Royal London Asset Management Ltd. Acquires 4,094 Shares of ResMed Inc. (NYSE:RMD)

Royal London Asset Management Ltd. lifted its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 76,812 shares of the medical equipment provider's stock after acquiring an additional 4,094 shares during the quarter. Royal London Asset Management Ltd. owned approximately 0.05% of ResMed worth $17,566,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RMD. Harvest Fund Management Co. Ltd lifted its position in shares of ResMed by 67.1% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 1,656 shares of the medical equipment provider's stock worth $379,000 after purchasing an additional 665 shares during the period. OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in ResMed by 139.5% in the fourth quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 46,584 shares of the medical equipment provider's stock worth $10,653,000 after buying an additional 27,132 shares during the period. Generali Asset Management SPA SGR bought a new stake in ResMed during the 4th quarter valued at approximately $4,196,000. Axxcess Wealth Management LLC grew its holdings in shares of ResMed by 63.0% during the 4th quarter. Axxcess Wealth Management LLC now owns 9,969 shares of the medical equipment provider's stock worth $2,280,000 after acquiring an additional 3,853 shares during the period. Finally, Parallel Advisors LLC raised its position in shares of ResMed by 6.4% in the 4th quarter. Parallel Advisors LLC now owns 1,697 shares of the medical equipment provider's stock worth $388,000 after acquiring an additional 102 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company's stock.

Remove Ads

ResMed Stock Performance

NYSE:RMD traded up $0.61 during trading hours on Wednesday, reaching $221.90. The company had a trading volume of 492,225 shares, compared to its average volume of 966,788. The firm's 50 day moving average price is $234.61 and its 200-day moving average price is $238.66. The firm has a market cap of $32.59 billion, a price-to-earnings ratio of 26.20, a PEG ratio of 1.53 and a beta of 0.74. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 52 week low of $172.19 and a 52 week high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, analysts forecast that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.96%. The ex-dividend date was Thursday, February 13th. ResMed's dividend payout ratio (DPR) is presently 25.03%.

Insider Buying and Selling

In related news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the transaction, the director now directly owns 77,218 shares in the company, valued at approximately $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kaushik Ghoshal sold 9,113 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $235.40, for a total value of $2,145,200.20. Following the sale, the insider now directly owns 9,725 shares of the company's stock, valued at $2,289,265. This represents a 48.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,940 shares of company stock valued at $9,164,385. 0.71% of the stock is owned by insiders.

Analyst Ratings Changes

RMD has been the topic of several recent research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research note on Friday, January 31st. UBS Group upgraded shares of ResMed from a "hold" rating to a "strong-buy" rating in a research note on Friday, January 31st. The Goldman Sachs Group began coverage on shares of ResMed in a research note on Thursday, January 16th. They set a "buy" rating on the stock. StockNews.com raised shares of ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday. Finally, Morgan Stanley initiated coverage on ResMed in a research report on Wednesday, March 19th. They issued an "overweight" rating and a $280.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $246.83.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.